|Bid||152.98 x 800|
|Ask||152.92 x 900|
|Day's Range||152.32 - 155.51|
|52 Week Range||117.64 - 169.98|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||201.82|
Subscribe to Yahoo Finance Plus to view Fair Value for JAZZ
HC Wainwright tweaked the price target on Jazz Pharmaceuticals plc (NASDAQ: JAZZ) to $204 with a reiterated Buy rating on slightly increased forward EPS estimates. Jazz reported a thorough 2Q22 beat, with broad product outperformance vs. consensus across neuro and oncology, plus gross margin upside and light OPEX, HC Wainwright notes. As per the analyst, this looked to be Jazz’s second-biggest operating cash flow quarter ever, pushing net leverage down to 3.2x, six months ahead of the targeted
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.